[Clinical evaluation of the use of proglumide in the treatment of the peptic ulcer semebrome]. / Valoración clínica del uso de la proglumida en el tratamiento del sindrome ulceroso
G E N
; 30(1-2): 125-31, 1975.
Article
em Es
| MEDLINE
| ID: mdl-829075
The authors have made a clinical evaluation of Proglumida in 27 patients suffering from Peptic ulcer. Proglumida was administered orraly, 2 tables of 200 mg 3 times a day, 1.200 mg in 24 hours, during a period varying from 21 to 28 days. The painful symptoms improved in 96% of the pain occurred in 59% during the first 7 days of treatment. The dispeptic symptoms improved in all cases, disappearing completely in 74%, but in a slower fashion than the pain, and in 68% of the cases only from the second week of treatment onward. The objectivation of the pain by palpation of the epigastrium improved in all cases and did so in a significant form in 59% of the cases during the first seven days of treatment. No undesireable side effects have been observed in any of the cases. We believe that Proglumida is a pharmacological drug of positive action in the treatment of the ulcer syndrome, because of its favorable action and the absence of secondary side effects.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proglumida
/
Úlcera Gástrica
/
Úlcera Duodenal
/
Glutamina
Limite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Es
Revista:
G E N
Ano de publicação:
1975
Tipo de documento:
Article
País de publicação:
Venezuela